OTCMKTS:OMGAQ Omega Therapeutics Q4 2023 Earnings Report $0.08 +0.01 (+22.89%) As of 12:52 PM Eastern ProfileEarnings HistoryForecast Omega Therapeutics EPS ResultsActual EPS-$0.37Consensus EPS -$0.46Beat/MissBeat by +$0.09One Year Ago EPSN/AOmega Therapeutics Revenue ResultsActual Revenue$0.99 millionExpected Revenue$0.93 millionBeat/MissBeat by +$60.00 thousandYoY Revenue GrowthN/AOmega Therapeutics Announcement DetailsQuarterQ4 2023Date3/28/2024TimeN/AConference Call DateThursday, March 28, 2024Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Omega Therapeutics Earnings HeadlinesOmega Therapeutics Inc (OMGAQ)March 5, 2025 | investing.comHuge distressed drugmaker seeks sale in Chapter 11 bankruptcyFebruary 27, 2025 | msn.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 14 at 2:00 AM | Brownstone Research (Ad)Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & ImmunologyFebruary 19, 2025 | markets.businessinsider.comOmega Therapeutics secures $9.8M in DIP financingFebruary 14, 2025 | msn.comOmega Therapeutics announces board reshuffle and new directorJanuary 29, 2025 | msn.comSee More Omega Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Omega Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omega Therapeutics and other key companies, straight to your email. Email Address About Omega TherapeuticsOmega Therapeutics (OTCMKTS:OMGAQ) is a clinical-stage biotechnology company focused on developing a new class of precision genetic medicines through its proprietary ECHELON™ platform. Headquartered in Boston, Massachusetts, the company applies programmable epigenetic control to selectively turn genes on or off, aiming to provide durable treatments for rare diseases, oncology and immunological disorders. Omega’s approach leverages synthetic DNA sequences to reprogram gene expression without permanently altering the genomic code. The ECHELON platform centers on synthetic cis-regulatory elements that guide endogenous cellular machinery to modulate target genes with spatial and temporal specificity. By combining computational design, high-throughput screening and advanced delivery technologies, Omega seeks to address previously undruggable targets. Its preclinical pipeline encompasses programs in rare neuromuscular diseases, solid tumors and autoimmune conditions, with collaboration agreements supporting clinical translation. Founded in 2019 by a team of researchers with backgrounds in genetics, molecular biology and drug development, Omega Therapeutics has expanded its operations to include laboratories in both North America and Europe. The company maintains partnerships with academic institutions and biopharma organizations to accelerate R&D efforts, while investing in scalable manufacturing capabilities to support future clinical and commercial needs. Omega’s leadership team combines seasoned executives from leading biotechnology and pharmaceutical firms with academic pioneers in gene regulation. The company’s management brings deep expertise in translational medicine, regulatory strategy and commercial development, supported by a scientific advisory board drawn from top-tier research institutions.Written by Jeffrey Neal JohnsonView Omega Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
